What is TYVASO®?

TYVASO is a direct-to-the-lungs, inhaled prostacyclin mimetic indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3).1

TYVASO’s direct-to-lung delivery results in higher concentrations of the drug in the pulmonary arterial vasculature.

TYVASO treats at the site of the disease

TYVASO is inhaled directly to distal airspaces that are in close proximity to pulmonary arterioles affected by pulmonary hypertension.2

Direct-to-lung delivery results in higher concentrations in the pulmonary arterial vasculature, which may selectively enhance blood flow for better ventilation and perfusion matching with less off-target exposure.3

TYVASO is delivered using an ultrasonic nebulizer, which means it is not dependent on your patient’s lung capacity.1,4,5

WHO=World Health Organization.